Leptospira IgM ELISA Evaluated Among Outpatients in Southern Asia
|
By LabMedica International staff writers Posted on 26 May 2021 |

Image: The Leptospira ELISA IgM assay (Photo courtesy of Panbio)
Leptospirosis is a widespread but neglected zoonotic disease caused by a bacterium of the genus Leptospira. Leptospirosis contributes to approximately 48,000 annual deaths globally, with 500,000 cases estimated worldwide, and remains a major public health concern in tropical and subtropical regions. Weil’s disease is a severe form of leptospirosis.
The serological “gold standard” for identifying pathogenic Leptospira is the microscopic agglutination test (MAT); however, it requires significant technical expertise and the maintenance of viable Leptospira serovars. Microscopic agglutination test is often not beneficial for acute patient management, mainly because it relies on immunoglobulins which react five days after the exposure.
Tropical Medicine specialists at Mahidol University (Salaya, Thailand) and their international colleagues evaluated a Leptospira ELISA IgM assay among 656 febrile outpatients attending primary care in Chiangrai, Thailand, and Hlaing Tha Yar, Yangon, Myanmar. Inclusion criterion was a documented fever (tympanic temperature > 37.5°C) or a complaint of acute fever (< 14 days). Of primary care children and adults recruited in the original trial, 799 were randomized in a control group for whom various samples were collected. From these 799 outpatients, 740 had a blood sample collected.
A commercial Leptospira ELISA IgM assay (Panbio Pty., Ltd., Windsor, Australia) was used for the detection of IgM antibodies against Leptospira spp. The manufacturer’s specifications were followed with Panbio units of ≥ 11.0 considered positive. Positive Leptospira IgM ELISA samples were then tested by MAT, with titers of ≥ 1:100 used to classify past exposure to leptospirosis. TaqMan Array Card (TAC) and single-plex PCR assays were performed on 601 blood samples where sufficient plasma volumes were able to be extracted. The TAC assay targeted all pathogenic serovars of the Leptospira genus, whereas the single-plex PCR used real-time methodology to target the rss gene.
The team reported that the ELISA demonstrated limited diagnostic accuracy for the detection of acute leptospiral infection using the manufacturer recommended cutoff, with a sensitivity of 71.4% and specificity of 36.4%, and an area under the receiver operator characteristic curve value of 0.65, compared with the reference test, the PCR assay. ELISA also performed poorly as a screening tool for detecting recent exposure to Leptospira spp. compared with the “gold-standard” MAT, with a specificity of 42.7%. The proportion of patients with a confirmed acute leptospirosis infection as defined by either single-plex or TAC PCR assay was 1.1% (7/656), whereas 23.5% (154/656) were seropositive by IgM ELISA.
The authors concluded that the IgM ELISA, although simple and widely used, was found to be unsuitable for detecting acute leptospirosis infection among outpatient children and adults attending primary care, using PCR assays as a reference method Even so, it is unlikely that such test, used on an acute sample, may represent an attractive candidate for the diagnosis of acute leptospirosis. The IgM ELISA was not specific as a screening method for recent exposure to pathogenic Leptospira. Using the MAT, the scientists demonstrated a significant exposure (30.5%) to pathogenic Leptospira among Thai and Myanmar communities, including rural and semi-urban settings. The study was published on May 5, 2021 in The American Journal of Tropical Medicine and Hygiene.
Related Links:
Mahidol University
Panbio Pty., Ltd
The serological “gold standard” for identifying pathogenic Leptospira is the microscopic agglutination test (MAT); however, it requires significant technical expertise and the maintenance of viable Leptospira serovars. Microscopic agglutination test is often not beneficial for acute patient management, mainly because it relies on immunoglobulins which react five days after the exposure.
Tropical Medicine specialists at Mahidol University (Salaya, Thailand) and their international colleagues evaluated a Leptospira ELISA IgM assay among 656 febrile outpatients attending primary care in Chiangrai, Thailand, and Hlaing Tha Yar, Yangon, Myanmar. Inclusion criterion was a documented fever (tympanic temperature > 37.5°C) or a complaint of acute fever (< 14 days). Of primary care children and adults recruited in the original trial, 799 were randomized in a control group for whom various samples were collected. From these 799 outpatients, 740 had a blood sample collected.
A commercial Leptospira ELISA IgM assay (Panbio Pty., Ltd., Windsor, Australia) was used for the detection of IgM antibodies against Leptospira spp. The manufacturer’s specifications were followed with Panbio units of ≥ 11.0 considered positive. Positive Leptospira IgM ELISA samples were then tested by MAT, with titers of ≥ 1:100 used to classify past exposure to leptospirosis. TaqMan Array Card (TAC) and single-plex PCR assays were performed on 601 blood samples where sufficient plasma volumes were able to be extracted. The TAC assay targeted all pathogenic serovars of the Leptospira genus, whereas the single-plex PCR used real-time methodology to target the rss gene.
The team reported that the ELISA demonstrated limited diagnostic accuracy for the detection of acute leptospiral infection using the manufacturer recommended cutoff, with a sensitivity of 71.4% and specificity of 36.4%, and an area under the receiver operator characteristic curve value of 0.65, compared with the reference test, the PCR assay. ELISA also performed poorly as a screening tool for detecting recent exposure to Leptospira spp. compared with the “gold-standard” MAT, with a specificity of 42.7%. The proportion of patients with a confirmed acute leptospirosis infection as defined by either single-plex or TAC PCR assay was 1.1% (7/656), whereas 23.5% (154/656) were seropositive by IgM ELISA.
The authors concluded that the IgM ELISA, although simple and widely used, was found to be unsuitable for detecting acute leptospirosis infection among outpatient children and adults attending primary care, using PCR assays as a reference method Even so, it is unlikely that such test, used on an acute sample, may represent an attractive candidate for the diagnosis of acute leptospirosis. The IgM ELISA was not specific as a screening method for recent exposure to pathogenic Leptospira. Using the MAT, the scientists demonstrated a significant exposure (30.5%) to pathogenic Leptospira among Thai and Myanmar communities, including rural and semi-urban settings. The study was published on May 5, 2021 in The American Journal of Tropical Medicine and Hygiene.
Related Links:
Mahidol University
Panbio Pty., Ltd
Latest Immunology News
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
- Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
- Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection
- Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
- Luminescent Probe Measures Immune Cell Activity in Real Time
- Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
- Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients
- Companion Diagnostic Test for CRC Patients Identifies Eligible Treatment Population
- Novel Tool Uses Deep Learning for Precision Cancer Therapy
- Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients
- Novel Multiplex Assay Supports Diagnosis of Autoimmune Vasculitis
- Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer
- Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients
- Novel Gene Signature Predicts Immunotherapy Response in Advanced Kidney Cancers
- New Technology Deciphers Immune Cell Communication to Predict Immunotherapy Response
Channels
Clinical Chemistry
view channel
VOCs Show Promise for Early Multi-Cancer Detection
Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read more
Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
Kidney disease is typically diagnosed through blood or urine tests, often when patients present with symptoms such as blood in urine, shortness of breath, or weight loss. While these tests are common,... Read moreMolecular Diagnostics
view channel
First Direct Measurement of Dementia-Linked Proteins to Enable Early Alzheimer’s Detection
The disease process in Alzheimer’s begins long before memory loss or cognitive decline becomes apparent. During this silent phase, misfolded proteins gradually form amyloid fibrils, which accumulate in... Read more
New Diagnostic Method Detects Pneumonia at POC in Low-Resource Settings
Pneumonia continues to be one of the leading causes of death in low- and middle-income countries, where limited access to advanced laboratory infrastructure hampers early and accurate diagnosis.... Read moreHematology
view channel
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read moreImmunology
view channel
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read more
Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. Many patients undergo costly and taxing treatment... Read morePathology
view channel
New Molecular Analysis Tool to Improve Disease Diagnosis
Accurately distinguishing between similar biomolecules such as proteins is vital for biomedical research and diagnostics, yet existing analytical tools often fail to detect subtle structural or compositional... Read more
Tears Offer Noninvasive Alternative for Diagnosing Neurodegenerative Diseases
Diagnosing and monitoring eye and neurodegenerative diseases often requires invasive procedures to access ocular fluids. Ocular fluids like aqueous humor and vitreous humor contain valuable molecular information... Read moreTechnology
view channel
Cell-Sorting Device Uses Electromagnetic Levitation to Precisely Direct Cell Movement
Sorting different cell types—such as cancerous versus healthy or live versus dead cells—is a critical task in biology and medicine. However, conventional methods often require labeling, chemical exposure,... Read more
Embedded GPU Platform Enables Rapid Blood Profiling for POC Diagnostics
Blood tests remain a cornerstone of medical diagnostics, but traditional imaging and analysis methods can be slow, costly, and reliant on dyes or contrast agents. Now, scientists have developed a real-time,... Read moreIndustry
view channel
Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
QIAGEN (Venlo, Netherlands) has entered into a definitive agreement to fully acquire Parse Biosciences (Seattle, WA, USA), a provider of scalable, instrument-free solutions for single-cell research.... Read more
Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
Puritan Medical Products (Guilford, ME, USA), the world’s most trusted manufacturer of swabs and specimen collection devices, is set to exhibit at AMP2025 in Boston, Massachusetts, from November 11–15.... Read more
Advanced Instruments Merged Under Nova Biomedical Name
Advanced Instruments (Norwood, MA, USA) and Nova Biomedical (Waltham, MA, USA) are now officially doing business under a single, unified brand. This transformation is expected to deliver greater value... Read more








